Skip to main content

20-10-2021 | Rheumatology | News | Article


EMA recommends expanding risankizumab indication to include PsA

Author: Shreeya Nanda

medwireNews: The EMA’s Committee for Medicinal Products for Human Use has recommended that the indication for the interleukin (IL)-23 inhibitor risankizumab be extended to include psoriatic arthritis (PsA).

Previously authorized in Europe for plaque psoriasis, risankizumab – either given alone or alongside methotrexate – is now also indicated for the treatment of active disease in people with an inadequate response or intolerance to at least one DMARD.

The clinical benefit of the IL-23 inhibitor was demonstrated in the KEEPsAKE 2 trial, in which response rates were significantly higher with risankizumab than placebo in patients who had an inadequate response to either conventional or biologic DMARDs.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group